1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy

The present invention pertains generally to the field of therapeutic compds., and more specifically to certain compds. of the following formula (I) (for convenience, collectively referred to herein as "IP compds.")​, which, inter alia, are useful in the treatment of cancer, e.g., cancer characterized by (e.g., driven by) mutant RAS ("mutant RAS cancer")​. The present invention also pertains to pharmaceutical compns. comprising such compds., and the use of such compds. and compns. in the treatment of cancer, e.g., mutant RAS cancer.